Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting Jeffrey Paul.

Slides:

Advertisements

Similar presentations

AFRT 8 nov 2002 A3-1 Why Another Antibiotic for Respiratory Tract Infections? C. Couturier.

Advertisements

Ketek ™ (Telithromycin) NDA Efficacy Review John Alexander, M.D., M.P.H. Medical Team Leader Division of Anti-Infective Drug Products.

CLINICAL EFFICACY Oral Telithromycin George Rochester, PhD, CCRN Statistical Reviewer Division of Biometrics III Division of Anti-infective Drug Products.

Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist Jeffrey J. Pasternak, MD, Eric E. Williamson,

My Treatment Approach to Hairy Cell Leukemia Rahul R. Naik, MD, Alan Saven, MD Mayo Clinic Proceedings Volume 87, Issue 1, Pages (January 2012) DOI:

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Protein Synthesis Inhibitors

Charles D. Burger, MD, Roger K. Resar, MD Mayo Clinic Proceedings

Managing Cancer Pain: Basic Principles and Invasive Treatments

R. Leclercq Clinical Microbiology and Infection

Ductal Carcinoma in Situ of the Breast

Vitamin D Insufficiency

Noninvasive Ventilation

Evaluation of Proteinuria

Helicobacter pylori Mayo Clinic Proceedings

Treatment of Nightmares With Prazosin: A Systematic Review

William L. Lanier, MD Mayo Clinic Proceedings

Diagnosis and Management of Chronic Kidney Disease

Shireen Mirza, MBBS, Roberto Benzo, MD Mayo Clinic Proceedings

Charles D. Burger, MD, Roger K. Resar, MD Mayo Clinic Proceedings

A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs Charles E. Argoff,

Michele A. Hanson, M.D., Daniel A. Dumesic, M.D.

Palliative Care and Hospice Programs

Topical Analgesics in the Management of Acute and Chronic Pain

69-Year-Old Woman With Rapid Heartbeat

Acupuncture Mayo Clinic Proceedings

Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program M.

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia C. Carbon, S. Moola,

Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations D. Andes, W.A. Craig Clinical Microbiology.

Community-acquired pneumonia: the evolving challenge

Pancreatic Ductal Adenocarcinoma

Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic.

MIGUEL A. VALDOVINOS, M. D. , MICHAEL CAMILLERI, M. D. , BRUCE R

Refurbishing Mayo Clinic Proceedings:

A. Bryskier Clinical Microbiology and Infection

Antidepressants and Brain Neurochemistry

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Community-acquired pneumonia in adults

Acquired Binocular Horizontal Diplopia

Best Practices for Patients With Chronic Migraine

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis S.R. Norrby, J. Quinn, M. Rangaraju,

Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin G. Drusano Clinical Microbiology and Infection

Evaluation and Management of Penicillin Allergy

Evaluating the Patient With Diarrhea: A Case-Based Approach

Institutional Review Boards: What Clinician Researchers Need to Know

Diabetic Mastopathy Mayo Clinic Proceedings

Novel Risk Factors for Atherosclerosis

Allen D. Seftel, MD, Martin Kathrins, MD, Craig Niederberger, MD

Hepatocellular Carcinoma

68-Year-Old Man With Chronic Diarrhea, Nausea, and Vomiting

Methylphenidate: Its Pharmacology and Uses

Postoperative Trouble

Pulmonary Tumor Embolism of Unknown Origin

Medical Treatment of Overactive Bladder: In Response

Hassanali H. Sewani, MD, Jeffrey T. Rabatin, MD

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

Mantle Cell Involvement of the Spleen

Squamous Cell Carcinoma of the Tongue

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Current Concepts in Laboratory Testing to Guide Antimicrobial Therapy

Medical Student Distress: Causes, Consequences, and Proposed Solutions

Identification of Acute Transplacental Hemorrhage in a Low-Risk Patient as a Result of Daily Counting of Fetal Movements ROBERT H. HEISE, M.D., Jo T.

Clomiphene-Induced Severe Hypertriglyceridemia and Pancreatitis

Managing Cancer Pain: Basic Principles and Invasive Treatments

Treatment of Antineutrophil Cytoplasm Autoantibody-Associated Systemic Vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical.

Diagnosis and Management of Headache in Older Adults

Acute and Chronic Seizures in Patients Older Than 60 Years

Mayo Clinic Proceedings 2012: “A New Era in Journal Stewardship”

Presentation transcript:

Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting Jeffrey Paul Clark, MD, Edward Langston, MD Mayo Clinic Proceedings Volume 78, Issue 9, Pages 1113-1124 (September 2003) DOI: 10.4065/78.9.1113 Copyright © 2003 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 1 Telithromycin inhibits bacterial protein synthesis by blocking peptidyl transferase activity. rRNA = ribosomal RNA. Mayo Clinic Proceedings 2003 78, 1113-1124DOI: (10.4065/78.9.1113) Copyright © 2003 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 2 Penetration of telithromycin at the site of infection and into bronchopulmonary fluids. Telithromycin concentrations (mg/L or mg/kg) in (A) plasma, (B) bronchial mucosa, (C) epithelial lining fluid, and (D) alveolar macrophages. BLQ = below limit of quantification. Mayo Clinic Proceedings 2003 78, 1113-1124DOI: (10.4065/78.9.1113) Copyright © 2003 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 3 Clinical cure and bacterial eradication rates with telithromycin, arranged by indication. AECB = acute exacerbations of chronic bronchitis; AS = acute sinusitis; CAP = community-acquired pneumonia; T/P = tonsillitis/pharyngitis. Mayo Clinic Proceedings 2003 78, 1113-1124DOI: (10.4065/78.9.1113) Copyright © 2003 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 4 Activity of telithromycin (800 mg once daily) against infections due to Streptococcus pneumoniae with reduced susceptibility to penicillin (PEN) or erythromycin (ERY); results are from 11 phase 3 clinical trials.85 ERY-R = erythromycin resistant; PEN-I = penicillin intermediate resistance; PEN-R = penicillin resistant. *74 of 81 isolates had a clinical cure; 75 of 81 isolates had a bacterial eradication. Mayo Clinic Proceedings 2003 78, 1113-1124DOI: (10.4065/78.9.1113) Copyright © 2003 Mayo Foundation for Medical Education and Research Terms and Conditions